Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer
Source: SeekingAlpha
2025-06-03 13:19:58 ET
Summary
- SMMT's HARMONi trial showed strong PFS benefit for ivonescimab in EGFR-mutant NSCLC, but overall survival data missed statistical significance so far.
- FDA approval hinges on a significant overall survival benefit, which remains unproven, creating regulatory uncertainty despite positive PFS results.
- Concerns persist over trial reproducibility and reliance on Chinese patient data, with global results showing diminished benefit compared to China-only studies.
- SMMT's $13B valuation already prices in massive success, but high near-term risks and lack of commercial clarity are cause for me to remain cautious on the stock.
Topline Summary and Update
Summit Therapeutics ( SMMT ) has kicked off one of the most important and interesting developing stories in solid tumor oncology over the past two years. Few were paying attention when they reported the findings from HARMONi-A around ASCO time in 2024 (coincidentally corresponding with a drop in share price ). ...
Read the full article on Seeking Alpha
For further details see:
Explaining Summit's Fall Despite Positive Data In EGFR-Positive Lung Cancer
Akeso
NASDAQ: AKESF
AKESF Trading
-7.84% G/L:
$17.05 Last:
400 Volume:
$18.90 Open:
